| XOMA Ltd. Q1 2010 Earnings Call Transcript XOMA Ltd. (XOMA)Q1 2010 Earnings Conference CallMay 6, 2010 4:30 PM ETComplete Story » seekingalpha.com |
8 Healthcare Sector Takeover Targets Kapitall submits:According to reports, French pharma giant Sanofi-Aventis (SNY) is considering making several U.S. biotech acquisitions; including one or two that could be worth at least $15 billion.On the news shares of Biogen (BIIB), Allergan (AGN) and Genzyme (GENZ) all shot higher.Complete Story » seekingalpha.com |
Don't Sleep Through Cephalon's Growth Ockham Research submits: Cephalon (CEPH) is a biopharmaceutical company that we have highlighted in the past, and it reported another outstanding quarter after the close on Tuesday. The company’s most successful drug is Provigil, which is used to treat some sleep disorders, but for some reason we think the market has been lulled into sleepiness when it comes to this growth story. The company reported revenue of $712.4 million, or 32% growth over the second quarter last year. Adjusted for income per share came in at $2.20 per share, 41% better than a year ago and $.43 cents better than Wall Street expected (that is after 9 analysts upped their targets in just the last month). The company experienced growth in all different categories of drugs with oncology drug Treanda being a standout from the bunch.Complete Story » seekingalpha.com |
FDA Reviewing Safety Information on Actos The Food and Drug Administration said Friday it has started a safety review of Takeda Pharmaceutical Co.'s diabetes drug Actos, looking at links to bladder cancer. online.wsj.com |
Bigger Doors Open for Aveo as Merck Deal Closes EP Vantage submits:It is normally taken as bad news when a big pharma partner hands back rights to a drug – unless you are Aveo Pharmaceuticals (AVEO). Shares in the Massachusetts company have surged 43% since Merck & Co (MRK) terminated a deal over lung cancer drug AV-299 last week, reaching a record high of $15 on Thursday. Aveo listed on Nasdaq in March and these gains mean the stock is the only US biotech IPO of 2010 to be trading above its offer price; a notable achievement. Investors appear convinced that Merck's decision does not reflect badly on AV-299 and are only looking at the potential for lucrative new deals to be struck. This certainly looks possible; the company now owns broad rights to two promising anti-cancer products, on which important phase II and III data are due next year, and has enough cash to last until then. With oncology remaining a hot area for deals and Aveo unencumbered by partners, the company is emerging as one to watch.Complete Story » seekingalpha.com |